Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
1. Is Wanbury Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Wanbury Ltd is a average quality company.
2. Is Wanbury Ltd undervalued or overvalued?
The key valuation ratios of Wanbury Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
3. Is Wanbury Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Wanbury Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||-0.9%||-17%||5.5%||7.4%||46.9%||-11.1%||6%||61.3%||11.2%||101.5%||-|
|Value Creation Index ⓘ||-1.1||NA||NA||NA||2.4||NA||NA||3.4||NA||6.3||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||6.5%||13.3%||-15.3%||2.5%||-14.5%||5.5%||-6.1%||6.8%||30.2%||-|
|Adj EPS ⓘ||-15.2||-32.6||-1.1||-3.3||24.9||-13.9||-10.4||2.5||-4.8||11||0.5|
|YoY Gr. Rt. %||-||NA||NA||NA||NA||-155.7%||NA||NA||-293.9%||NA||-|
|BVPS (₹) ⓘ||39.9||-64.1||-193||-99.3||-54.9||-67.2||-77.5||-47.2||-52.4||0.3||-1.4|
|Adj Net Profit ⓘ||-26.5||-65.2||-2.2||-6.6||57.8||-32.9||-24.6||6.2||-11.9||35.8||2|
|Cash Flow from Ops. ⓘ||18.2||49.1||80.1||43.2||43.4||32.5||29.7||44.1||16.7||40.5||-|
|Debt/CF from Ops. ⓘ||22.8||5.3||9.5||8.7||6.2||6.8||7.8||3.7||9.6||1.7||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||-15.1%||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||-20.8||376.5||0.7||4||-39.8||23||14.4||-4.1||9.6||-55.7||-81.7|
|Op. Profit Mgn % ⓘ||3.9||6.9||8.6||7.9||4.3||-18.2||3.6||-5.9||4.3||6.4||7.5|
|Net Profit Mgn % ⓘ||-6.4||-14.8||-0.4||-1.6||13.3||-8.9||-6.3||1.7||-3||7||0.3|
|Debt to Equity ⓘ||6||-2||-2||-1.9||-2.1||-1.4||-1.3||-1.4||-1.2||71.5||-|
|Working Cap Days ⓘ||282||147||295||162||159||127||74||86||78||84||0|
|Cash Conv. Cycle ⓘ||46||21||15||2||-17||-51||-59||-81||-77||-65||0|
No data to display
Return on Equity is Poor
Sales growth has been subdued in last 3 years 9.31%
Net Profit has been subdued in last 3 years 0.00%
Debt to equity has increased versus last 3 years average to 71.51
Sales growth is not so good in last 4 quarters at 6.17%
|TTM EPS (₹)||0.5||0.5|
|TTM Sales (₹ Cr.)||529||529|
|BVPS (₹.) ⓘ||-1.4||-9.3|
|Reserves (₹ Cr.) ⓘ||-37||-63|
|From the Market|
|52 Week Low / High (₹)||33.05 / 70.90|
|All Time Low / High (₹)||0.85 / 267.00|
|Market Cap (₹ Cr.)||224|
|Equity (₹ Cr.)||32.7|
|Face Value (₹)||10|
|Industry PE ⓘ||41.7|
Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.
Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanburyâ€™s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.
The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.
Product range of the company includes:
2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded â€˜Best Brand Launchâ€™ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.
2007Doctorâ€™s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded â€˜Best Brand Launchâ€™ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.
2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the worldâ€™s largest producer of Metformin with production of 4500 MT.
2005Wanbury acquired Doctorâ€™s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product APIâ€™s.
2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.
2002Pearl Organics got US FDA approval for Patalganga plant.
1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.
1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).
1992Pearl Organics established its first plant in Tarapur for manufacturing APIâ€™s.
1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.
1990Incorporated as Pearl Distributors Pvt